Immunohistochemistry and biochemistry data

In the single Tau[P301L] transgenic mice, hTAU is expressed under control of the mouse Thy-1 promoter. The observed tau conformational change and age-dependent accumulation of AT8 and AT100 reactive insoluble tau have been proposed to trigger age-dependent tangle pathology in the brain stem, starting at age 7-8 months (figure 1). In parallel, and with a strong correlation in time, the Tau[P301L] mice develop motor deficits like limb clasping and reduced survival, i.e. succumbing before the age of 12 months.

In other behavioral test, like the beam walk, we also observe a progressive motor phenotype with age in the Tau[P301L] mice. The latency strongly increases with age in these mice compared to wild type FVB/N mice (figure 2).

In these Tau[P301L] mice, we have already proven that Tau levels can be reduced after a chronic treatment of anti-tau specific antibodies. Figure 3 shows a significant reduction of hyperphosphorylated Tau in the STH/ZI and LAT/IntA/P areas of the brain after anti-tau mAb treatment from 3 to 9 months. This chronic treatment also reduces the motoric deficit, reflected by a reduction in clasping phenotype.

: AT8 (phospho S202/T205) and AT100 (phospho S212/T214)

Figure 1: AT8 (phospho S202/T205) and AT100 (phospho S212/T214) reactive cells in the midbrain of single transgenic Tau[P301L] mice. Tangle pathology shows a strong correlation with clasping phenotype. Quantification data is available on request.

beam walk

Figure 2: The latency to walk a beam over a distance of 1 meter strongly increases with age in single transgenic Tau[P301L] mice.

Significant reduction of hyperphosphorylated Tau and clasping phenotype
Clasping phenotype

Figure 3: Significant reduction of hyperphosphorylated Tau and clasping phenotype after chronic anti-tau mAb treatment in single transgenic Tau[P301L] mice compared to placebo treated Tau[P301L] mice.

Data on cognition and long term potentiation

BMS showed, in collaboration with reMYND, dose-dependent effects of sub-chronic donepezil on brain Aβ and cognition in APP[V717I]xPS1 mice. This study showed a significant improvement in reference memory in APPxPS1 mice along with a dose-dependent reduction in brain Aβ (figure 2). These results suggest that donepezil may alleviate cognitive impairments in Alzheimer’s disease, in part, by reducing brain Aβ.

LTP measurements in CA1 region

Figure 4: LTP measurements in CA1 region of 4-6 months-old Tau[P301L] animals compared to wild type animals and other transgenic Alzheimer models (Chong et all, 2011).

Passive inhibitory avoidance test

Figure 5: Passive inhibitory avoidance test with 5 months-old Tau[P301L] mice compared to age-matched non-transgenic control animals. This result shows a significant Passive Avoidance behavior for the transgenic Tau[P301L] mice. Terwel et al 2005, Terwel et al 2008, Theunis et al 2013, Griswold Prenner et al 2014 (P301L)

Data on microgliosis, astrocytosis and neuronal loss

The role of microglia and astrocytes in Alzheimer’s disease and how these contribute to neuronal loss has gained increased interest over the past years. Progressive astrocytosis and microgliosis have now been found in reMYND’s transgenic hTauP301L model as well (Figure 6).

The hTauP301L transgenic mouse model displays a robust motoric phenotype correlating with an age dependent increase in hyperphosphorylated Tau and the formation of neurofibrillary tangles.  Anti-CD68 and anti-GFAP immunohistological staining show a significant 3 to 4-fold increase in the CD68 and GFAP reactive area in aged hTauP301L mice (Figure 6), which is indicative for microgliosis and astrocytosis (Walker and Lue, 2015, Ben Haim et al., 2015).

Anti-GFAP and anti-CD68

Figure 6: Anti-GFAP (left) and anti-CD68 (right) immunohistological staining in the interposed cerebellar nucleus, anterior and posterior part (deep cerebellar nuclei). Old hTauP301L mice (9.3 months of age (9.3 mo) – advanced neurofibrillary tangle pathology) are compared with non-Tg control mice (9.3 mo) and young hTauP301L (5 mo – absence of neurofibrillary tangles). Quantifications are shown as % reactive area of the region of interest relative to the % reactive area for the non-Tg control mice.. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Aged hTauP301L mice (9.3 months of age) displaying neurofibrillary tangle pathology were compared with non-Tg controls (9.3 months of age) and young hTau.P301L mice (5.0 months of age) without any neurofibrillary tangle pathology (Figure 7). The increase in activation of microglia and astrocytes correlates with the level of neurofibrillary tangle pathology observed (Figure 8).

AT8 and AT100

Figure 7: AT8 (pSer202 and pThr205, left) and AT100 (pThr212 and pSer214, right) immunohistological staining in the interposed cerebellar nucleus, anterior and posterior part (deep cerebellar nuclei). Quantifications are shown as % reactive area of the region of interest. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Correlation of astrocytosis and microgliosis with neurofibrillary tangle pathology

Figure 8: Correlation of astrocytosis and microgliosis with neurofibrillary tangle pathology. The % reactive area for AT100 (pThr212 and pSer214) is plotted against the relative reactive area for GFAP (left) and CD68 (right). R square is 0.5798 and 0.6986 for GFAP and CD68, respectively.

Neuronal loss, a pathological hallmark of Alzheimer’s disease, is recapitulated in reMYND’s transgenic human hTauP301L mouse model. Immunohistochemical staining and quantification of NeuN positive neuronal nuclei of 9 month old hTauP301L mice demonstrate a 20 % neuronal loss in the subthalamic nucleus in comparison to age- and sex-matched control mice and the younger hTau.P301L mice (5 months) (Figure 9).

anti-NeuN in the subthalamic nucleus

Figure 9: anti-NeuN in the subthalamic nucleus - zona incerta. Quantifications are shown as % reactive area of the region of interest and relative to the NeuN reactive area in non-trangenic controls (100%). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Non-Tg: non-transgenic control mice

In comparison to the 5 months old hTauP301L mice and wild type controls, the aged hTauP301L mice show a prominent neurofibrillary tangle pathology (Figure 10, AT8 and AT100) indicating that the Tau pathology is steered by transgenic expression of human TauP301L drives neuronal loss

Immunohistological staining in the interposed cerebellar nucleus

Figure 10: AT8 (pSer202 and pThr205, left) and AT100 (pThr212 and pSer214, right) immunohistological staining in the interposed cerebellar nucleus, anterior and posterior part (deep cerebellar nuclei). Quantifications are shown as % reactive area of the region of interest. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

References

A proprietary data package on the Tau[P301L] model can be obtained upon request. Hereto, and for all other inquiries please contact Bart Roucourt, CRO Manager.